SCHEMBL5409796

SCHEMBL5409796

COc1ccc(S(=O)(=O)Nc2nc(C(C)C)ns2)cc1OC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.56
ALDH1A1 P00352 4/20 0.56
MEN1 O00255 3/20 0.56
PKM P14618 1/20 0.56
SCN9A Q15858 1/20 0.56
STAT3 P40763 1/20 0.55
SMN1; SMN2 Q16637 2/20 0.52
LMNA P02545 1/20 0.52
HTT P42858 1/20 0.52
CA12 O43570 1/20 0.50
CA9 Q16790 1/20 0.50
MAPK1 P28482 1/20 0.49
FFAR4 Q5NUL3 1/20 0.49
MAPT P10636 1/20 0.48
HPGD P15428 1/20 0.48
ALOX15 P16050 1/20 0.48
TSHR P16473 1/20 0.48
KEAP1 Q14145 1/20 0.48
NFE2L2 Q16236 1/20 0.48
TP53 P04637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5399376 0.81 SCN9A (0.56) KMT2AALDH1A1MEN1PKMSCN9A
SCHEMBL5402218 0.80 KDM4E (0.52) KMT2APKMSCN9ASMN1; SMN2EDNRA
SCHEMBL5391638 0.79 MAPT (0.51) KMT2AALDH1A1MEN1SCN9AHTT
SCHEMBL633157 0.79 STAT3 (0.58) KMT2AALDH1A1MEN1PKMSCN9A
SCHEMBL5391600 0.78 SCN9A (0.50) KMT2AALDH1A1MEN1PKMSCN9A
SCHEMBL5404967 0.78 SCN9A (0.48) KMT2AMEN1PKMSCN9ASMN1; SMN2
SCHEMBL5391554 0.77 SCN9A (0.48) KMT2AALDH1A1MEN1PKMSCN9A
SCHEMBL5386367 0.77 SCN9A (0.49) KMT2AALDH1A1SCN9AMAPT
SCHEMBL5397811 0.76 ALDH1A1 (0.56) ALDH1A1PKMSCN9ASMN1; SMN2LMNA
SCHEMBL5391539 0.76 NMT1 (0.50) ALDH1A1SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070066614-A1 Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2007-03-22 US claimed
US-7173030-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2007-02-06 US claimed
EP-1631558-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2006-03-08 EP claimed
US-20050009821-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2005-01-13 US claimed
WO-2004103980-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2004-12-02 WO claimed
US-20070066614-A1 Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2007-03-22 US disclosed
US-7173030-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2007-02-06 US disclosed
EP-1631558-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2006-03-08 EP disclosed
US-20050009821-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2005-01-13 US disclosed
WO-2004103980-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2004-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009821-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 KMT2A 3325/4885ALDH1A1 53/4885MEN1 942/4885
US-20070066614-A1 Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD17B11 KMT2A 3281/4885ALDH1A1 36/4885MEN1 974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.